帕金森病相关脑代谢模式与孤立性快速眼动睡眠行为障碍中的神经退行性变
该前瞻性队列研究纳入30例iRBD、25例伴RBD的新发PD、21例长期治疗PD和24例健康对照,从FDG-PET提取PD-RP和dnPDRBD-RP两种代谢模式。dnPDRBD-RP与iRBD患者嗅觉相关并预测表型转化,PD-RP与运动评分相关。
要点
- dnPDRBD-RP代谢模式可预测iRBD向神经退行性疾病转化。
- dnPDRBD-RP与iRBD患者丁醇阈值嗅觉测试相关。
- PD-RP与MDS-UPDRS运动评分相关,但与iRBD嗅觉无关。
核心结论
- dnPDRBD-RP是反映PD前驱特征并预测iRBD表型转化的有效神经影像生物标志物,可个体化应用。
研究设计与样本
- 前瞻性队列研究纳入30例iRBD、25例伴RBD的新发PD、21例长期治疗PD和24例健康对照,iRBD组纵向随访。
- 另用14例独立iRBD队列验证代谢模式。
主要发现
- PD-RP与dnPDRBD-RP显著相关,空间重叠但不同。
- MDS-UPDRS运动评分与PD-RP显著相关(p=0.013),与dnPDRBD-RP无显著相关(p=0.076)。
- iRBD患者中dnPDRBD-RP与丁醇阈值测试嗅觉相关(p=0.018),PD-RP不相关(p=0.21)。
- iRBD患者高dnPDRBD-RP在对照值1.5至3 SD所有截断范围均预测未来表型转化,PD-RP仅在部分截断范围显著。
临床怎么用
- FDG-PET衍生的dnPDRBD-RP评分可用于iRBD患者个体化预测向神经退行性疾病转化。
局限性
- 证据等级为Class IV,预测效能需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To elucidate the role of Parkinson disease (PD)-related brain metabolic patterns as a biomarker in isolated REM sleep behavior disorder (iRBD) for future disease conversion. METHODS: This is a prospective cohort study consisting of 30 patients with iRBD, 25 patients with de novo PD with a premorbid history of RBD, 21 patients with longstanding PD on stable treatment, and 24 healthy controls. The iRBD group was longitudinally followed up. All participants underwent 18F-fluorodeoxyglucose (FDG) PET and were evaluated with olfaction, cognition, and the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at baseline. From FDG-PET scans, we derived metabolic patterns from the longstanding PD group (PD-RP) and de novo PD group with RBD (dnPDRBD-RP). Subsequently, we calculated the PD-RP and dnPDRBD-RP scores in patients with iRBD. We validated the metabolic patterns in each PD group and separate iRBD cohort (n = 14). RESULTS: The 2 patterns significantly correlated with each other and were spatially overlapping yet distinct. The MDS-UPDRS motor scores significantly correlated with PD-RP (p = 0.013) but not with dnPDRBD-RP (p = 0.076). In contrast, dnPDRBD-RP correlated with olfaction in butanol threshold test (p = 0.018) in patients with iRBD, but PD-RP did not (p = 0.21). High dnPDRBD-RP in patients with iRBD predicted future phenoconversion with all cutoff ranges from 1.5 to 3 SD of the control value, whereas predictability of PD-RP was only significant in a partial range of cutoff. CONCLUSION: The dnPDRBD-RP is an efficient neuroimaging biomarker that reflects prodromal features of PD and predicts phenoconversion in iRBD that can be applied individually. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that a de novo PD pattern on FDG-PET predicts future conversion to neurodegenerative disease in patients with iRBD.
引用
- Shin JH, Lee JY, Kim YK, et al. Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder. Neurology. 2021. PMID: 34011571. doi:10.1212/WNL.0000000000012228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。